- Hypertrophic Cardiomyopathy (HCM)
- Eyecare
- Urothelial Carcinoma
- Hemophilia
- Heart Failure
- Vaccines
- Neonatal Care
- NSCLC
- Type II Inflammation
- Substance Use Disorder
- Gene Therapy
- Lung Cancer
- Spinal Muscular Atrophy
- HIV
- Post-Acute Care
- Liver Disease
- Asthma
- Atrial Fibrillation
- COVID-19
- Cardiovascular Diseases
- Prescription Digital Therapeutics
- Reproductive Health
- The Improving Patient Access Podcast
- Blood Cancer
- Ulcerative Colitis
- Respiratory Conditions
- Multiple Sclerosis
- Digital Health
- Population Health
- Sleep Disorders
- Biosimilars
- Plaque Psoriasis
- Leukemia and Lymphoma
- Oncology
- Pediatrics
- Urology
- Obstetrics-Gynecology & Women's Health
- Opioids
- Solid Tumors
- Autoimmune Diseases
- Dermatology
- Diabetes
- Mental Health
Emerging trends affect PBM industry
Besides an ongoing trend of mergers and acquisitions, other issues are shaping the PBM market, say experts.
BESIDES AN ONGOING TREND of mergers and acquisitions, other issues are shaping the PBM market, say experts.
These trends include:
UNIQUE BENEFIT DESIGNS
"These changes include larger cost differences for members among tiers while maintaining low out-of-pocket expenses for members using the lowest tier," Solberg explains.
The first tier historically has included all generics but now often includes generics or brands that target key disease management classes.
SPECIALTY PHARMACY
Payers are looking to PBMs to help manage specialty drug spend by making sure that patients have access to the right drugs at the right time and for the correct indications while helping to control costs in this very expensive niche area, according to Ruth Ann C. Opdycke, PharmD, MS, president, TPG Healthcare Consulting LLC, Glastonbury, Conn. "The average cost of a 30-day supply for a specialty drug is well over $1,500," Dr. Opdycke says. "Specialty trend is increasing at double the rate of traditional drug spend."
HSAs
More employers are choosing to offer HSAs and other types of CDHPs as a way to control health premiums. "Employers are looking for tools that help members choose the right plan and identify high-quality, cost-effective treatment options," Solberg says.
E-PRESCRIBING
Electronic prescribing and the transmission of complementary information such as benefit design parameters, formulary status and utilization management edits to prescribers at the point of care will drastically change today's healthcare paradigm, Solberg says.
ALTERNATIVE PRICING MODEL
Some PBMs and payers are discussing pricing models based on net drug acquisition cost plus a base PBM administrative fee, says Dr. Opdycke.
-Tracey Walker
What Payers Need to Know As Retail Pharmacies Move Into Primary Care
September 6th 2023Healthcare beyond the doors of the doctor’s office has the potential to offer more care to more people. But payers need to think about how to ensure that care is consistent. Regardless of the setting, care decisions must be based on evidence-based content and supported with strong patient education.
Read More
David Calabrese of OptumRx Talks New Role, Market Insulin Prices and Other Topics 'On His Mind'
April 13th 2023In this month’s episode of the "What's On Your Mind podcast," Peter Wehrwein, managing editor of MHE connects with the now Chief Clinical Officer of OptumRx Integrated Pharmacies, David Calabrese. In this conversation, David touches on his transition in January as OptumRx’s former chief pharmacy officer and market president of health plans and PBMs to his new role as Chief Clinical Officer where he now focuses more on things such as specialty pharmacy to home delivery — with an overall goal of creating whole-patient care. Throughout the conversation, Calabrese also touched on the market’s hot topic of insulin prices and behavioral health services within the OptumRx community, among other topics.
Listen
Addressing the Barriers of Medication Adherence Through Digital Health
July 9th 2023Tony Little, ND, VP of Solutions Architecture at Prescryptive Health, shares how the organization is tackling one of the biggest barriers to prescription adherence — cost — through a digital app, among the other barriers patients face.
Read More
Briana Contreras, editor of Managed Healthcare Executive, spoke with Nancy Lurker, CEO and president of EyePoint Pharmaceuticals. Nancy shared a bit about EyePoint and how the organization’s innovative therapies are addressing patient needs through eye care, and most importantly, she addressed C-Suite positions like the CEO role. Nancy shared advice for those seeking to reach the CEO level, especially toward women in healthcare and other roles, and what it takes to run a biopharma company.
Listen
